# Mechanisms and applications of natural plant ingredients in modulating amino acid metabolism for the improvement of diabetic retinopathy: a review

## TL;DR

This review explores how natural plant compounds may help treat diabetic retinopathy by targeting amino acid metabolism and reducing oxidative stress and inflammation.

## Contribution

The paper systematically reviews the role of amino acid metabolism in diabetic retinopathy and evaluates the therapeutic potential of natural plant-derived compounds.

## Key findings

- Flavonoids, catechins, and alkaloids modulate amino acid metabolism and show antioxidant and anti-inflammatory effects in preclinical models.
- Glutamate, arginine, and tryptophan metabolism are key in diabetic retinopathy pathogenesis, with plant compounds offering potential therapeutic targets.
- Natural compounds like berberine improve retinal microcirculation and endothelial function by regulating nitric oxide synthesis.

## Abstract

Diabetic Retinopathy (DR) is a leading cause of vision loss in diabetic patients, driven by oxidative stress, inflammation, and vascular abnormalities. Recent studies highlight amino acid metabolism abnormalities, particularly in glutamate, arginine, and tryptophan, as critical factors in DR pathogenesis. Preclinical evidence suggests that these metabolic disturbances may contribute to retinal neurodegeneration and vascular damage, offering potential new targets for therapy. Natural plant-derived compounds, such as flavonoids, catechins, and alkaloids, have been shown in animal and cell culture studies to regulate amino acid metabolism and may offer therapeutic potential for DR, although clinical validation remains limited. These compounds exhibit antioxidant, anti-inflammatory, and neuroprotective properties. Flavonoids improve amino acid accumulation, reduce oxidative stress, and protect retinal cells, while catechins enhance amino acid synthesis and redox balance. Alkaloids like berberine regulate nitric oxide synthesis, improving retinal microcirculation and endothelial function. In DR, glutamate excess activates NMDA receptors, leading to retinal neuronal toxicity, while arginine and tryptophan metabolism abnormalities further disrupt vascular and immune function. Natural drugs targeting these pathways could alleviate oxidative stress, inflammation, and retinal damage. However, challenges remain in clinical application, including low bioavailability and variability in product quality. Future research should focus on multi-omics integration, personalized medicine, and clinical trials to establish robust evidence for the use of natural drugs in DR treatment, ultimately improving long-term visual outcomes and quality of life.